ML-007 is a selective muscarinic acetylcholine M1 and M4 receptor agonist which is under development for the treatment of schizophrenia, psychotic disorders, and dyskinesias. It is being developed in combination with a peripherally selective muscarinic acetylcholine receptor antagonist (also known as ML-007/peripherally acting anticholinergic or ML-007/PAC). The drug is taken orally. It produces antipsychotic-like effects in rodents, including inhibition of amphetamine and phencyclidine (PCP)-induced hyperlocomotion and activity in the conditioned avoidance response test. These effects appear to dependent on activation of both muscarinic acetylcholine M1 and M4 receptors. The drug is approximately 10-fold more potent than xanomeline in these tests. As of January 2024, ML-007 is in phase 1 clinical trials for schizophrenia, psychotic disorders, and dyskinesias. It is under development by MapLight Therapeutics. The drug is a small molecule, but its chemical structure does not seem to have been disclosed.
See also List of investigational antipsychotics Emraclidine NBI-1117568 NS-136 Xanomeline/trospium (KarXT)
References